This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NeoStem And Progenitor Cell Therapy (PCT) To Present At Multiple May Conferences

NEW YORK, May 5, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in May.

Regenerative Medicine Foundation 2014 Conference

Session 1:

  • Date and Time: Monday, May 5, 2014, 4:15 PM PST
  • Panelist: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Leveraging Standards to Expedite Clinical Product Delivery and Biobanking Services

Session 2:

  • Date and Time: Tuesday, May 6, 2014, 2:15 PM PST
  • Panelist: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Product Development Towards Commercialization in Regenerative Medicine

Terrapinn's 9 th Annual World Stem Cells & Regenerative Medicine Congress 2014

Session 1:

  • Date and Time: Tuesday, May 20, 2014, 5:15 PM BST
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: Case Study: AMR-001 for post AMI: enhancing the body's healing response

Session 2:

  • Date and Time: Wednesday, May 21, 2014, 2:30 PM BST
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Understanding the path to bring your cell therapy to market

Session 3:

  • Date and Time: Thursday, May 22, 2014, 9:35 AM BST
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: Understanding market place acceptance and market positioning of your cell therapy

Third Annual Marcum Microcap Conference

  • Date and Time: Thursday, May 29, 2014, 11:30 AM EST
  • Venue: Grand Hyatt New York, 109 East 42 nd Street, New York, NY
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: Company Presentation
  • Website: www.marcumllp.com/microcap

BioKorea 2014 International Convention

Session 1 - Overview of Stem Cell and Regenerative Medicine Industry:

  • Date and Time: Thursday, May 29, 2014 10:00 AM KST
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Title: State of the RM Industry in the US and Global

Session 2 - Rapid Snapshots of Stem Cell and Regenerative Medicine Companies:

  • Date and Time: Thursday, May 29, 2014 4:30 PM KST
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Title: Alliance's Technology and Research Achievements

11 th International Symposium on Stem Cell Therapy

Session 1:

  • Date and Time: Thursday, May 29, 2014, 5:20 PM CEST
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Exosomes and cardiac repair after myocardial infarction

Session 2:

  • Date and Time: Thursday, May 29, 2014, 6:30 PM CEST
  • Panelist: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Clinical research in stem cell therapy: Advances, barriers and pitfalls

Session 3:

  • Date and Time: Friday, May 30, 2014, 11:30 AM CEST
  • Panel Chair: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Late Breaking Clinical Trials

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com   

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's ability to consummate the CSC acquisition and the Company's ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's CD34 Cell Program and T Regulatory Cell Program and other cell therapies (including Melapuldencel-T if CSC is successfully acquired), the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact:
         LifeSci Advisors, LLC
         Michael Rice
         Founding Partner
         Phone: +1-646-597-6979
         Email: mrice@lifesciadvisors.com
         
         Media Contact:
         NeoStem, Inc.
         Eric Powers
         Manager of Communications and Marketing
         Phone: +1-212-584-4173
         Email: epowers@neostem.com

NeoStem Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs